Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Objectives: To evaluate the real-world benefits and safety of mucosal sublingual immunotherapy based on whole inactivated bacteria (MV130) in preventing WA in children.
The omadacycline fixed-dosing strategy showed consistent safety and real-world benefits in patients with CABP of different body sizes.
Although the JAVELIN Lung 200 primary analysis (reported previously) revealed that avelumab did not significantly prolong OS versus docetaxel in patients with platinum-treated PD-L1+ NSCLC, posthoc analyses at 2 years of...
After 8 weeks of treatment, the percentage changes from baseline in non-HDL-C (-4.4% vs +0.6%; p = 0.02) and triglycerides (-18.5% vs +0.9%; p 2 ), or without diabetes.
Conclusion: MCMs are well suited to modeling long-term survival in acute myeloid leukemia patients.
Liver enzyme levels were significantly lower in the intervention group (p γ cytokine levels were significantly reduced in the intervention group (p β were significantly increased in the intervention group (P < 0.05).Overall,...
Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time.
Efficacy of romosozumab on clinical fracture, osteoporotic fracture, and MOF is significantly greater in patients at high baseline fracture risk compared with placebo.
Secukinumab improved enthesitis at overall MASES and axial sites in patients with AS.
Adding lixisenatide to BI significantly reduced HbA1c and 2-h PPG levels in both Asian and white participants with type 2 diabetes.
Treatment of moderate to severe LCL with Neuronox ® was effective and well-tolerated.
Hazard ratios for PFS per BICR and per INV were consistent, with no suggestion of investigator bias.
GPB 1% cream may provide an effective new treatment option exhibiting a good safety profile for patients with PAHH.
FIL200 + MTX real-world benefits and safety in patients with multiple PPFs were similar to the overall population.
No cases of IBD were observed and rates of GI SAEs were low through 4 years of treatment with guselkumab in two large trials of patients with psoriasis.
For patients with NSTI undergoing surgical management, persistent organ dysfunction at 14 days, strongly predicts higher resource utilization, poor discharge disposition, and higher long-term mortality.
Nivolumab is likely to be cost-effective for the treatment of patients with advanced NSCLC following platinum-based chemotherapy in the United States.
To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well...
The optimal intervention should be targeted to cognitive decline in the early stages of dementia.
These population PK analyses characterize activity-time profiles for rFVIIIFc among children and adult subjects.
Plasma ruxolitinib concentrations after treatment with applied to the skin ruxolitinib cream in patients with up to 20% BSA affected by AD are not expected to lead to systemic plasma concentrations that may be associated with...
In an updated analysis from the phase III MONALEESA‐3 trial with more than 4.5 years of follow‐up, ribociclib plus fulvestrant maintained a significant overall survival benefit compared with fulvestrant alone in postmenopausal...
Alpelisib plus fulvestrant provides long‐term disease control in patients with endocrine‐resistant, HR‐positive, HER2‐negative, PIK3CA‐mutated advanced breast cancer, according to an updated analysis from the SOLAR‐1 and X2101...
OCT 0.1% mouthwash inhibits plaque formation over 5 days.
As in patients with GC, FTD/TPI showed an efficacy benefit in patients with GEJC in the TAGS trial, along with demonstrating a manageable safety profile.
No notable AEs occurred because of the UPA treatment, and the incidence of AEs in the UPA group was comparable with that of AEs in the LEU group.
Female patients had significantly higher incidences of grade 2+ IMAEs than male patients.
These findings complement the sustained and significant improvement in progression-free survival observed with D-Rd and supports its use in patients with RRMM.
Only marginal covariate effects were observed, and thus no dose adjustments are deemed necessary for FF, UMEC, or.
Neither drug modified the frequencies of IL-17A + IL ‒ 17F + / - CD4 + or CD8 + T cells.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
